{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:46:02Z","timestamp":1791402362329,"version":"4.3.3"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.braindev.2025.104397","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:10:03Z","timestamp":1753359003000},"page":"104397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Duchenne muscular dystrophy: Evolving therapeutic strategies and multidimensional evaluation approaches"],"prefix":"10.1016","volume":"47","author":[{"given":"Hirofumi","family":"Komaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.braindev.2025.104397_bb0005","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","article-title":"Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis","volume":"35","author":"Landfeldt","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.braindev.2025.104397_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.104467","article-title":"Early diagnosis of Duchenne muscular dystrophy - a Treat-NMD international workshop","volume":"45","author":"Lorentzos","year":"2024","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2025.104397_bb0015","doi-asserted-by":"crossref","DOI":"10.1177\/22143602251324858","article-title":"Antisense RNA therapies for muscular dystrophies","author":"Arechavala-Gomeza","year":"2025","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"10.1016\/j.braindev.2025.104397_bb0020","article-title":"Phase 1\/2 trial of brogidirsen: dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy","volume":"6","author":"Komaki","year":"2025","journal-title":"Cell Rep Med"},{"issue":"8","key":"10.1016\/j.braindev.2025.104397_bb0025","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.braindev.2025.104397_bb0030","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"Torres-Masjoan","year":"2025","journal-title":"Mol Ther"},{"issue":"8023","key":"10.1016\/j.braindev.2025.104397_bb0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.braindev.2025.104397_bb0040","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of Vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.braindev.2025.104397_bb0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2025.104397_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950651","article-title":"Drug development progress in Duchenne muscular dystrophy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.braindev.2025.104397_bb0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12015-023-10653-8","article-title":"Cell therapy strategies on Duchenne muscular dystrophy: a systematic review of clinical applications","volume":"20","author":"Akat","year":"2024","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"10.1016\/j.braindev.2025.104397_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.23808","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.braindev.2025.104397_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"Scott","year":"2012","journal-title":"Physiother Res Int"},{"issue":"10","key":"10.1016\/j.braindev.2025.104397_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307118","article-title":"Characterization of patients with Duchenne muscular dystrophy across previously developed health states","volume":"19","author":"Muntoni","year":"2024","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.braindev.2025.104397_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the north star ambulatory assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"Muntoni","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.braindev.2025.104397_bb0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/mus.23902","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.braindev.2025.104397_bb0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/dmcn.14361","article-title":"Performance of upper limb module for Duchenne muscular dystrophy","volume":"62","author":"Mayhew","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.braindev.2025.104397_bb0090","first-page":"947","article-title":"Non-invasive respiratory assessment in Duchenne muscular dystrophy: from clinical research to outcome measures","volume":"11","author":"Pennati","year":"2021","journal-title":"Life (Basel)"},{"issue":"4","key":"10.1016\/j.braindev.2025.104397_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.braindev.2025.104397_bb0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JND-210743","article-title":"Stride velocity 95th centile: insights into gaining regulatory qualification of the first wearable-derived digital endpoint for use in Duchenne muscular dystrophy trials","volume":"9","author":"Servais","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"17","key":"10.1016\/j.braindev.2025.104397_bb0105","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1093\/hmg\/ddv214","article-title":"Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies","volume":"24","author":"Rouillon","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"15","key":"10.1016\/j.braindev.2025.104397_bb0110","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddaa132","article-title":"Serum biomarkers associated with baseline clinical severity in young steroid-naive Duchenne muscular dystrophy boys","volume":"29","author":"Dang","year":"2020","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2025.104397_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.921785","article-title":"Novel miRNA biomarkers for patients with Duchenne muscular dystrophy","volume":"13","author":"Meng","year":"2022","journal-title":"Front Neurol"},{"issue":"13","key":"10.1016\/j.braindev.2025.104397_bb0120","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1212\/WNL.0000000000008939","article-title":"MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy","volume":"94","author":"Naarding","year":"2020","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.braindev.2025.104397_bb0125","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.braindev.2025.104397_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195850","article-title":"Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy","volume":"13","author":"Beekman","year":"2018","journal-title":"PLoS One"},{"issue":"10\u221211","key":"10.1016\/j.braindev.2025.104397_bb0135","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41434-021-00300-7","article-title":"Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy","volume":"29","author":"Farrokhi","year":"2022","journal-title":"Gene Ther"},{"key":"10.1016\/j.braindev.2025.104397_bb0140","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/ph14080798","article-title":"Genetic modifiers and phenotype of Duchenne muscular dystrophy: A systematic review and meta-analysis","volume":"14","author":"Pascual-Morena","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.braindev.2025.104397_bb0145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1055\/s-0037-1604110","article-title":"Translational research in Europe for the assessment and treatment for neuromuscular disorders (TREAT-NMD)","volume":"48","author":"Leary","year":"2017","journal-title":"Neuropediatrics"},{"issue":"4","key":"10.1016\/j.braindev.2025.104397_bb0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.nmd.2022.02.009","article-title":"Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the north star ambulatory assessment for comparisons with external controls","volume":"32","author":"Muntoni","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.braindev.2025.104397_bb0155","doi-asserted-by":"crossref","first-page":"e1381","DOI":"10.1212\/WNL.0000000000010170","article-title":"Suitability of external controls for drug evaluation in Duchenne muscular dystrophy","volume":"95","author":"Goemans","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.braindev.2025.104397_bb0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11136-022-03240-w","article-title":"A comprehensive qualitative framework for health-related quality of life in Duchenne muscular dystrophy","volume":"32","author":"Powell","year":"2023","journal-title":"Qual Life Res"},{"issue":"6410","key":"10.1016\/j.braindev.2025.104397_bb0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.braindev.2025.104397_bb0170","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1016\/j.braindev.2025.104430","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000}}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760425000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:00:58Z","timestamp":1764403258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760425000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0387760425000798"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104397","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duchenne muscular dystrophy: Evolving therapeutic strategies and multidimensional evaluation approaches","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2025.104397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Society of Child Neurology. Elsevier B.V. CC BY 4.0","name":"copyright","label":"Copyright"}],"article-number":"104397"}}